Abstract 750P
Background
The RUBY trial (NCT03981796) evaluated the efficacy and safety of dostarlimab (D)+carboplatin-paclitaxel (CP) vs CP alone in pA/rEC. D+CP significantly improved progression-free survival (PFS) in the mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H; HR, 0.28) and overall population (HR, 0.64) with a favorable OS trend (HR, 0.64). Here, PFS2 and OS adjusted for subsequent anticancer therapy are reported.
Methods
Pts were randomised 1:1 to receive D+CP or placebo (PBO)+CP Q3W for 6 cycles, followed by D or PBO monotherapy Q6W for up to 3 years. PFS2 was a secondary endpoint for the dMMR/MSI-H and overall populations. Post hoc treatment switching-adjustment (for subsequent use of dostarlimab, pembrolizumab, durvalumab, nivolumab, or pembrolizumab with lenvatinib) was implemented using 2 methods: inverse probability of censoring weighting (IPCW) and rank-preserving structural failure time (RPSFT).
Results
Of 494 pts randomised (D+CP, n=245; PBO+CP, n=249), 118 were dMMR/MSI-H (D+CP, n=53; PBO+CP, n=65). Overall, 15.5% of pts in the D+CP arm and 34.5% of pts in the PBO+CP arm received subsequent immunotherapy. PFS2 benefit was observed with D+CP for all populations (Table). When adjusted for subsequent therapy, the HRs for OS for D+CP vs PBO+CP for both IPCW and RPSFT were similar to the unadjusted HR for OS in all populations, with increased survival with D+CP (Table). Safety was reported previously.
Conclusions
Consistent with results of the primary efficacy analysis, dostarlimab+CP demonstrates PFS2 and OS benefits vs PBO+CP in pts with pA/rEC despite the use of subsequent therapies. These results provide additional support for the use of dostarlimab+CP as standard of care in pts with pA/rEC. Table: 750P
dMMR/MSI-H | MMRp/MSS | Overall | ||||
Variable, HR (95% CI) | D+CP N=53 | PBO+CP N=65 | D+CP N=192 | PBO+CP N=184 | D+CP N=245 | PBO+CP N=249 |
PFS a | 0.28 (0.16–0.50) P<0.0001 | 0.76 (0.59–0.98) | 0.64 (0.51–0.80) P<0.0001 | |||
PFS2 | 0.37 (0.19–0.73) | 0.71 (0.54–0.95) | 0.65 (0.50–0.84) | |||
Subsequent immunotherapy, n (%) | 8 (15.1) | 25 (38.5) | 30 (15.6) | 61 (33.2) | 38 (15.5) | 86 (34.5) |
OS | 0.30 (0.13–0.70) | 0.73 (0.52–1.02) | 0.64 (0.46–0.87) P=0.0021 | |||
IPCW, n | 52 | 65 | 188 | 181 | 240 | 246 |
IPCW-adj OS | 0.35 (0.12–1.00) | 0.67 (0.44–1.03) | 0.62 (0.42–0.90) | |||
RPSFT, n | 53 | 65 | 192 | 184 | 245 | 249 |
RPSFT-adj OS | 0.24 (0.09–0.67) | 0.69 (0.47–1.03) | 0.59 (0.41–0.85) | |||
Acceleration factor b | 3.465 | 1.408 | 1.613 |
aInvestigator assessment per RECIST v1.1 bD+CP increases survival by AF
.Clinical trial identification
NCT01847274.
Editorial acknowledgement
Writing and editorial support, funded and coordinated by GSK, was provided by Shannon Morgan-Pelosi, PhD, and Mary C. Wiggin, of Ashfield MedComms, an Inizio company.
Legal entity responsible for the study
GSK.
Funding
GSK.
Disclosure
B.M. Slomovitz: Financial Interests, Personal, Advisory Board: AstraZeneca, Clovis, Eisai, GSK, Genentech, Merck, Immunogen, Novocure; Financial Interests, Personal, Other, consultant: GOG Foundation; Non-Financial Interests, Member of Board of Directors: GOG Foundation. N. Raaschou-Jensen: Financial Interests, Personal, Advisory Board: Eisai. R.L. Coleman: Financial Interests, Personal, Advisory Board: AstraZeneca, agenus, Alkermes, Immunogen, Roche/Genentech, GSK, Genmab/Seagen, Epsilogen, Myriad Genetics; Financial Interests, Personal, Invited Speaker: AstraZeneca, Genmab/Seagen; Non-Financial Interests, Principal Investigator: abbvie, immunogen, Roche/Genentech, Merck, Genmab, Clovis; Non-Financial Interests, Project Lead, MyLung Consortium: US Oncology Research. L. Gilbert: Financial Interests, Institutional, Funding: Alkermes, AstraZeneca, Clovis, Esperas, IMV, ImmunoGen Inc, Karyopharm, Merck Sharp & Dohme, Mersana, Novocure GmbH, OncoQuest Pharmaceuticals, Pfizer, Roche, Tesaro; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, Alkermes, AstraZeneca, Eisai, Eisai-Merck, GSK. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Tesaro, Merck, Eisai, Seagen, Clovis Oncology, AstraZeneca. D. Cibula: Financial Interests, Personal, Advisory Board: Roche, SOTIO, Novocure, MSD, GSK, Akesobio, Seagen; Financial Interests, Personal, Invited Speaker: AstraZeneca. S. Ghamande: Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Advisory Board, also invited speaker: GSK; Financial Interests, Institutional, Coordinating PI, Clinical trial payments: GSK, Jounce; Financial Interests, Institutional, Coordinating PI, Clinical trial payment: Merck, Eisai; Financial Interests, Institutional, Coordinating PI, clinical trial payments: Mersana, AstraZeneca; Non-Financial Interests, Advisory Role: GOG foundation. B. Ataseven: Financial Interests, Personal, Speaker, Consultant, Advisor, also support for attending meetings: AstraZeneca, GSK, Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai, MSD, Novartis; Financial Interests, Personal, Advisory Board: Sanofi Aventis. D. Black: Financial Interests, Institutional, Funding: GSK; Financial Interests, Personal, Member of Board of Directors: GOG Partners Investigational Council; Financial Interests, Personal, Other: Trials365, LLC. L.J. Willmott: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Eisai, Immunogen, Merck, Seagen; Financial Interests, Personal, Advisory Board: AstraZeneca, Immunogen, Seagen. C. McCourt: Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Personal, Speaker, Consultant, Advisor: Washington University. O. Doehring, J. Garside: Financial Interests, Personal, Full or part-time Employment: GSK. T.J. Herzog: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Caris, Clovis, Eisai, Epsilogen, Genentech, GSK, Immunogen, Johnson & Johnson, Merck, Mersana, Seagen. M.R. Mirza: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Karyopharm, Merck, Roche, Zailab; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK; Financial Interests, Personal, Member of Board of Directors: Karyopharm; Financial Interests, Personal, Stocks/Shares: Karyopharm; Financial Interests, Institutional, Research Grant: GSK, AstraZeneca, Ultimovacs, Apexigen; Financial Interests, Institutional, Trial Chair: Deciphera; Non-Financial Interests, Advisory Role: Ultimovacs, Apexigen. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11